Cargando…
Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol metabolism by targeting the low-density lipoprotein receptor. Recent studies have shown that circulating PCSK9 is associated with glucose homeostasis and insulin resistance. The aim of this study was to examine t...
Autores principales: | Shi, Jie, Zhang, Weiwei, Niu, Yixin, Lin, Ning, Li, Xiaoyong, Zhang, Hongmei, Hu, Renming, Ning, Guang, Fan, Jiangao, Qin, Li, Su, Qing, Yang, Zhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726879/ https://www.ncbi.nlm.nih.gov/pubmed/33302966 http://dx.doi.org/10.1186/s12933-020-01185-3 |
Ejemplares similares
-
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Cardiometabolic Risk Factors: A Population-Based Cohort Study
por: Shi, Jie, et al.
Publicado: (2021) -
Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
por: Wu, Na-Qiong, et al.
Publicado: (2022) -
Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9
por: Chen, I-Chih, et al.
Publicado: (2017) -
Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
por: Ferri, Nicola, et al.
Publicado: (2020) -
Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
por: Shafiq, Muhammad, et al.
Publicado: (2020)